159 related articles for article (PubMed ID: 23801674)
1. Characterization of different osteosarcoma phenotypes by PET imaging in preclinical animal models.
Campanile C; Arlt MJ; Krämer SD; Honer M; Gvozdenovic A; Brennecke P; Fischer CR; Sabile AA; Müller A; Ametamey SM; Born W; Schibli R; Fuchs B
J Nucl Med; 2013 Aug; 54(8):1362-8. PubMed ID: 23801674
[TBL] [Abstract][Full Text] [Related]
2. Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [
Collantes M; Martínez-Vélez N; Zalacain M; Marrodán L; Ecay M; García-Velloso MJ; Alonso MM; Patiño-García A; Peñuelas I
BMC Cancer; 2018 Nov; 18(1):1193. PubMed ID: 30497448
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
[TBL] [Abstract][Full Text] [Related]
4. (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation.
Arvanitis C; Bendapudi PK; Tseng JR; Gambhir SS; Felsher DW
Cancer Biol Ther; 2008 Dec; 7(12):1947-51. PubMed ID: 18981708
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution, pharmacokinetics and PET imaging of [(18)F]FMISO, [(18)F]FDG and [(18)F]FAc in a sarcoma- and inflammation-bearing mouse model.
Liu RS; Chou TK; Chang CH; Wu CY; Chang CW; Chang TJ; Wang SJ; Lin WJ; Wang HE
Nucl Med Biol; 2009 Apr; 36(3):305-12. PubMed ID: 19324276
[TBL] [Abstract][Full Text] [Related]
6. Is Use of BMP-2 Associated with Tumor Growth and Osteoblastic Differentiation in Murine Models of Osteosarcoma?
Kendal JK; Singla A; Affan A; Hildebrand K; Al-Ani A; Ungrin M; Mahoney DJ; Itani D; Jirik FR; Monument MJ
Clin Orthop Relat Res; 2020 Dec; 478(12):2921-2933. PubMed ID: 33275394
[TBL] [Abstract][Full Text] [Related]
7. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
[TBL] [Abstract][Full Text] [Related]
8. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma.
Huang TL; Liu RS; Chen TH; Chen WY; Hsu HC; Hsu YC
J Chin Med Assoc; 2006 Aug; 69(8):372-6. PubMed ID: 16970273
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
[TBL] [Abstract][Full Text] [Related]
10. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma.
Franzius C; Bielack S; Flege S; Sciuk J; Jürgens H; Schober O
J Nucl Med; 2002 Aug; 43(8):1012-7. PubMed ID: 12163625
[TBL] [Abstract][Full Text] [Related]
12. Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcoma.
Miot-Noirault E; Gouin F; Dauplat MM; Heymann D; Chezal JM; Redini F
Cancer Biother Radiopharm; 2012 Feb; 27(1):96-103. PubMed ID: 22217151
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
[TBL] [Abstract][Full Text] [Related]
14. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
15. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors.
Sørensen M; Horsman MR; Cumming P; Munk OL; Keiding S
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):854-61. PubMed ID: 15936570
[TBL] [Abstract][Full Text] [Related]
16. Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases.
Yuan J; Ossendorf C; Szatkowski JP; Bronk JT; Maran A; Yaszemski M; Bolander ME; Sarkar G; Fuchs B
Cancer Invest; 2009 May; 27(4):435-42. PubMed ID: 19212826
[TBL] [Abstract][Full Text] [Related]
17. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
18. NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours.
Wyss MT; Honer M; Schubiger PA; Ametamey SM
Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):311-8. PubMed ID: 16258762
[TBL] [Abstract][Full Text] [Related]
19. Tumoral hypoxia in osteosarcoma in rats: preliminary study of blood oxygenation level-dependent functional MRI and 18F-misonidazole PET/CT with diffusion-weighted MRI correlation.
Dallaudiere B; Hummel V; Hess A; Lincot J; Preux PM; Maubon A; Monteil J
AJR Am J Roentgenol; 2013 Feb; 200(2):W187-92. PubMed ID: 23345383
[TBL] [Abstract][Full Text] [Related]
20. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
